Pro-Dex (NASDAQ:PDEX) Stock Crosses Above Two Hundred Day Moving Average of $18.59

Pro-Dex, Inc. (NASDAQ:PDEX) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $18.59 and traded as high as $20.99. Pro-Dex shares last traded at $20.70, with a volume of 6,851 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 5th.

Pro-Dex Stock Up 1.2 %

The firm has a market capitalization of $71.65 million, a PE ratio of 36.12 and a beta of 0.37. The firm’s 50-day moving average is $19.02 and its 200 day moving average is $18.59. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.08 and a current ratio of 3.45.

Insider Buying and Selling at Pro-Dex

In other news, Director Angelita Rebamontan Domingo sold 2,585 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $18.30, for a total transaction of $47,305.50. Following the completion of the transaction, the director now directly owns 8,191 shares of the company’s stock, valued at approximately $149,895.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 42.60% of the company’s stock.

Institutional Trading of Pro-Dex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PDEX. Dimensional Fund Advisors LP grew its holdings in shares of Pro-Dex by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after buying an additional 3,067 shares in the last quarter. Renaissance Technologies LLC boosted its position in Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after acquiring an additional 900 shares during the last quarter. Finally, Perritt Capital Management Inc. grew its stake in Pro-Dex by 43.3% in the 1st quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier’s stock worth $106,000 after acquiring an additional 1,813 shares during the period. Hedge funds and other institutional investors own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.